Former Deputy Attorney General called in to advise Valeant after fraud allegations
pharmafile | November 2, 2015 | Appointment | Medical Communications, Sales and Marketing |Â Â Mark Filip, Philidor, Valeant, fraudÂ
Valeant Pharmaceuticals’ board of directors has appointed former Deputy Attorney General of the United States Mark Filip to advise the pharma company during its review of mounting prescription fraud allegations.
The investigation relates to Valeant’s business relationship with US pharmacy chain Philidor. Valean has distanced itself from Philidor after allegations emerged that Philidor modified doctors’ prescriptions in order to boost reimbursements from insurers for the Canada-based company.
“We are pleased to have someone with Mark’s distinguished qualifications advise our committee,” says Robert Ingram, Valeant’s lead independent director. “The committee will be meeting promptly to determine the work plan for its review in consultation with counsel.”
Filip is a partner at Kirkland & Ellis LLP, where he leads the law firm’s government enforcement defense and internal investigations group, and he helps to lead the litigation department. He is an expert in white-collar crime and regulatory breaches.
Prior to joining Kirkland, Filip was at the US Department of Justice, where he served as Deputy Attorney General of the United States after being unanimously confirmed by the US Senate. As Deputy Attorney General, Mark was second-in-command of the Justice Department and oversaw all of its criminal and civil enforcement efforts.
He also served as Acting Attorney General for the new administration in 2009, until Attorney General of the United States, Eric Holder, was confirmed. Prior to serving as Deputy Attorney General, Filip spent four years as a federal judge in the US District Court for the Northern District of Illinois.
Related Content
CEO of PixarBio Corporation sentenced to prison for defrauding investors
Frank Reynolds, the CEO of Boston based PixarBio Corporation, was sentenced to seven years in …
Teva settles $135 million dollar fraud case over Medicaid price inflation
Israeli multinational Teva Pharmaceuticals has agreed to pay $135 million after being accused of fraudulently …
Digital system may prevent £300m prescription fraud losses for NHS by 2020
The British government are launching a new digitised system aimed at cracking down on prescription …
